SREBF1 and diabetic kidney disease: Wu used the NLRP3-specific inhibitor MCC950 and NLRP3 KO mice to demonstrate that NLRP3 stimulates fatty acid synthesis in diabetic nephropathy through increased expression of the fatty acid synthesis genes SREBP1 and SREBP2 (Wu et al., 2021).